

Emergency Rashes for the Hospitalist

Dr. Becca Gaffney

Associate Physician, BWH Dermatology

rgaffney@bwh.harvard.edu

Slides courtesy of Dr. Alexandra Charrow



Brigham and Women's Hospital
Founding Member, Mass General Brigham



**HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL**

Goals

- Develop tools to diagnose, differentiate, and treat the most severe and worrisome (and common) rashes:
 - Morbilliform rash
 - Stevens-Johnsons Syndrome
 - DRESS
 - AGEP
- Identify instances in which consultation/elevation of care will be most helpful


Case 1

54-year-old woman with past medical history of knee replacement 1 month ago who presents with a rash





Similar rash in darker-skinned individual



What additional information will help you assess this patient?

- HISTORY:
 - Medication history
 - Infection history
 - Immunologic status
- SYMPTOMS:
 - Skin pain vs skin itch
 - Mucosal involvement
- LABS:
 - CBC with DIFF, LFTs, BMP

Always the same




History

- Total knee replacement (TKR complicated by infection. Admitted and started on **cefepime** → Narrowed to **daptomycin** (PICC and discharged)
- Febrile again, Dx with PNA, 5 days ago, **levoflox** added
- Afib with RVR 4 days ago, initiated on **metop**, **dilt**, then discharged home

Re-presents to the ED now with RASH



HOW TO MAKE A DRUG CHART



Determining Mucosal Involvement

- 1) Mouth pain, ulceration, difficulty eating
- 2) Gritty sensation in the eyes
- 3) Pain with urination or sexual activity
- 4) Abnormal urinary stream

History (continued)

- Labs:
 - CBC: WBC today is 8
 - Diff is normal, **2% eos**
 - CMP: normal
 - Coags: normal
- Symptoms:
 - **No mucosal involvement**
 - **No skin pain**



Based on the information provided what is the most likely diagnosis?

- A. Stevens-Johnson's Syndrome (SJS)
- B. Acute generalized exanthematous pustulosis (AGEP)
- C. Morbilliform drug eruption
- D. Drug reaction with eosinophilia and systemic symptoms (DRESS)
- E. Atypical beta blocker-induced desquamating eruption

*Based on the information provided what is the most likely diagnosis?


- A. Stevens-Johnson's Syndrome (SJS)
- B. Acute generalized exanthematous pustulosis (AGEP)
- C. Morbilliform drug eruption!!
- D. Drug reaction with eosinophilia and systemic symptoms (DRESS)
- E. Atypical beta blocker-induced desquamating eruption



Diagnosis

- Morbilliform Rash- **Type 4 hypersensitivity reaction**
- Lacks mucosal involvement, rarely has skin pain (generally itch > pain)
- Medication history suggestive of rash
- Medication within 7 - 14 days of rash





Noe M. Morbilliform Drug Eruption. Inpatient dermatology. Cham:
Springer. 2018 Nov 3:13-6.

What is the most likely drug culprit for this morbilliform drug eruption?

- A. Cefepime
- B. Daptomycin
- C. Levofloxacin
- D. Metoprolol
- E. Diltiazem

What is the most likely drug culprit for this morbilliform drug eruption?

- A. Cefepime
- B. Daptomycin
- C. Levofloxacin
- D. Metoprolol
- E. Diltiazem

DRUG CHART




Table 2. Allergic Cutaneous Reactions to Drugs Received by at Least 1000 Patients (BCDSP)*

Drug	Reactions, No.	Recipients, No.	Rate, %	95% Confidence Interval
Amoxicillin	63	1225	5.1	3.9-6.4
Ampicillin	215	4763	4.5	3.9-5.1
Co-trimoxazole	46	1235	3.7	2.7-4.8
Semisynthetic penicillins	41	1436	2.9	2.0-3.7
Red blood cells	67	3386	2.0	1.5-2.4
Penicillin G	68	4204	1.6	1.2-2.0
Cephalosporins	27	1781	1.5	0.9-2.1
Gentamicin	13	1277	1.0	0.5-1.6

SKIN REACTIONS TO "DRUGS" RECEIVED BY AT LEAST 1000 PATIENTS

Drugs	Reaction rate (per 1000 recipients)
Ampicillin	52
Penicillin G	16
Cephalosporins	13
Packed red blood cells	8.1
Heparin	7.7
Nitrazepam	6.3
Barbiturates	4.7
Chlordiazepoxide	4.2
Diazepam	3.8
Propoxyphene	3.4
Guaifenesin	2.9
Furosemide	2.6
Phytonadione	0.9
Flurazepam	0.5
Chloral hydrate	0.2

Table 5. Allergic Cutaneous Reactions to Drugs Received by at Least 1000 Patients (van der Linden et al²)

Drug	Reactions, No.	Recipients, No.	Rate, %	95% Confidence Interval
Floroquinolones	16	1015	1.6	0.8-2.3
Amoxicillin	40	3233	1.2	0.9-1.6
Augmentin (SmithKline Beecham, Philadelphia, Pa)	12	1000	1.2	0.5-1.9
Penicillins	63	5914	1.1	0.8-1.3
Nitrofurantoin	7	1085	0.6	0.2-1.1
Tetracycline	23	4981	0.5	0.3-0.7
Macrolides	5	1435	0.3	0.0-0.7

Morbilliform Rash Causes


Treatment

- **High potency topical steroid ointment** applied BID to the body, avoiding face, genitals for up to 14 days.
- Stop medication
- Continue to monitor for signs of other skin reactions (mucosal involvement)
- Morbilliform rash will NEVER evolve into a more serious rash but should monitor for other symptoms incase of **misdiagnosis**



Topical Steroids

- Ointment > cream for penetration, but pick what the patient will use
- Lowest potency: **hydrocortisone 2.5%**
 - Good for use on face
- Medium potency: **triamcinolone 0.1%**
 - Good for body bc comes in 1g jar
- High potency: **clobetasol 0.05%** or Diprolene (betamethasone dipropionate)
 - Avoid on face and thin areas of body (skin folds, eyelids)
- Dosed BID X 2 weeks



Case 2

27 yo female with no past medical history presents to the ED with rash, skin pain, chapped lips.



Brigham and Women's Hospital
Founding Member, Mass General Brigham



**HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL**



Brigham and Women's Hospital
Founding Member, Mass General Brigham

Photo courtesy of Alexandra Charrow, MD. Do not reprint




**HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL**



Take 30 seconds to write down a description of the rash





Brigham and Women's Hospital
Founding Member, Mass General Brigham

Photo courtesy of Alexandra Charrow, MD. Do not reprint



**HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL**

What additional information will help you assess this patient?

- HISTORY:
 - Medication history
 - Infection history
 - Immunologic status
- SYMPTOMS:
 - Skin pain vs skin itch
 - Mucosal involvement
- LABS:
 - CBC with DIFF, LFTs, BMP



Determining Mucosal Involvement

- 1) Mouth pain, ulceration, difficulty eating
- 2) Gritty sensation in the eyes
- 3) Pain with urination or sexual activity
- 4) Abnormal urinary stream

Full History

27-year-old female, presented to her primary care 10 days ago with **paronychia**

- 10 days ago started on **cephalexin, ibuprofen, acetaminophen**
- 7 days ago, no improvement, initiated **TMP SMX**
- 1 day ago noted **skin pain**, initiated on **prednisone**
- **Notes some eye itchiness**
- **Labs: Mild leukocytosis to 10**



Based on the information provided what is the most likely diagnosis?

- A. Stevens-Johnson's Syndrome (SJS)
- B. Acute generalized exanthematous pustulosis (AGEP)
- C. Morbilliform drug eruption
- D. Drug reaction with eosinophilia and systemic symptoms (DRESS)
- E. Atypical beta blocker-induced desquamating eruption



Based on the information provided what is the most likely diagnosis?

- A. Stevens-Johnson's Syndrome (SJS)
- B. Acute generalized exanthematous pustulosis (AGEP)
- C. Morbilliform drug eruption
- D. Drug reaction with eosinophilia and systemic symptoms (DRESS)
- E. Atypical beta blocker-induced desquamating eruption

Diagnosis

- Concern for Stevens-Johnson Syndrome (SJS)
- Diagnosis can be made based on following:
 - Patients must have convincing medication history (>95% of cases associated with a medication)
 - Skin pain (not just itch)
 - Mucosal involvement
 - Biopsy can help to demonstrate skin necrosis

Table III. Diagnostic features of toxic epidermal necrolysis*

Clinical features	Histologic features
Constitutional symptoms: fever, malaise, anorexia, and pharyngitis	Full thickness epidermal necrosis
Erythematous, dusky, violaceous macules, morbilliform or atypical targetoid macules starting on the trunk and spreading distally; confluence on face, trunk, and elsewhere: TEN > SJS/TEN overlap > SJS	Subepidermal split, lymphocytic infiltrate at the dermoepidermal junction, CD4 ⁺ T cells in dermis, and CD8 ⁺ T cells in epidermis
Manifests in flaccid bullae, epidermal sloughing, and necrosis with gray hue	Endothelial apoptosis
Exfoliation of the epidermis involving 10% of body surface area for SJS, 10-30% for SJS/TEN overlap, and >30% for TEN	
Oral, genital, and ocular mucositis in nearly all patients	
Tender skin and painful mucosal erosions	
Positive Nikolsky sign	
Positive Asboe–Hansen sign	
Systemic symptoms always present in SJS/TEN overlap and TEN	
Respiratory tract epithelial involvement in 25% of patients with TEN	

SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.

*Data from Hazin et al,²⁷ Kamada et al,³⁴ Sedghizadeh et al,³⁵ and Edell et al.³⁶




Other Examination Features



British Journal of Dermatology (2016) 174, pp1194–1227

SPECTRUM OF DISEASE BASED UPON SURFACE AREA OF EPIDERMAL DETACHMENT



<10%

10-30%

>30%

□ = Surface area of epidermal detachment ■ = Detached epidermis

SJS = Stevens-Johnson syndrome TEN = Toxic epidermal necrolysis

SJS and TEN

Table 3 SCORTEN calculation

Age > 40 years
Presence of malignancy
Heart rate > 120 beats min⁻¹
Epidermal detachment > 10% BSA at admission
Serum urea > 10 mmol L⁻¹
Serum glucose > 14 mmol L⁻¹
Bicarbonate < 20 mmol L⁻¹

BSA, body surface area.

Table 4 SCORTEN predicted mortality

Number of parameters	Predicted mortality (%)
0	1
1	4
2	12
3	32
4	62
5	85
6	95
7	99



*Which is the most common cause of the patient's rash?

- A. Cephalexin
- B. TMP SMX
- C. Acetaminophen
- D. Ibuprofen
- E. Antecedent bacterial infection



*Which is the most common cause of the patient's rash?

- A. Cephalexin
- B. TMP SMX!**
- C. Acetaminophen
- D. Ibuprofen
- E. Antecedent bacterial infection



DRUG CHART




Table 2. Most Common Causes of Drug-Induced SJS/TEN (N = 338)¹

Class of Medication	n (%)
Antibiotics	165 (48.8)
Trimethoprim/sulfamethoxazole	89 (26.3)
β-lactam antibiotics	42 (12.4)
Fluoroquinolones	12 (3.6)
Antiepileptics/mood stabilizers	83 (23.7)
Phenytoin	32 (9.5)
Lamotrigine	30 (8.9)
Carbamazepine	7 (2.1)
Phenobarbital	4 (1.2)
Allopurinol	29 (8.6)
NSAIDs ²	18 (5.3)

Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; SJS/TEN, Stevens-Johnson syndrome; toxic epidermal necrolysis.

¹See [Supplementary Table S2](#) for a complete list of suspected causes of SJS/TEN.

²NSAIDs are listed individually in [Supplementary Table S2](#).



You are the admitting resident. Based on the morbidity that patients experience from SJS-TEN, **who should be consulted earliest?** Take 2 minutes to develop a plan for this pt (pair and share)

- A. Dermatology
- B. OB/GYN
- C. Ophthalmology
- D. Oral medicine
- E. Urology

You are the admitting resident. Based on the morbidity that patients experience from SJS-TEN, **who should be consulted earliest?** Take 2 minutes to develop a plan for this pt (pair and share)

- A. Dermatology
- B. OB/GYN
- C. Ophthalmology**
- D. Oral medicine
- E. Urology

Table 3 Spectrum of chronic ocular complications in Stevens–Johnson syndrome/toxic epidermal necrolysis

Anatomic site	Complications
Lids	Ectropion, entropion, trichiasis, distichiasis, lagophthalmos
Conjunctiva	Persistent hyperaemia, symblepharon, ankyloblepharon, forniceal shortening
Cornea	Superficial punctate keratopathy, loss of palisades of Vogt, epithelial defects, corneal scarring, neovascularization, keratinization, infectious keratitis, corneal thinning
Others	Chronic photosensitivity, decreased visual acuity, lacrimal duct obstruction, dry eyes

MANAGEMENT

- **STOP the causative medication**
- **Supportive care:**
 - Petroleum jelly, xeroform to affected areas, do not break blisters
 - Mouth care: Lidocaine mouthwash, topical steroids to the mouth, dexamethasone wash
 - **Topical high-potency steroids**
- **Consultants:**
 - Dermatology
 - **Ophtho for corneal protection**
 - Gyn for dilator placement; foley placement for men
 - +/- burn depending on degree of insensible losses



Treatment

- IV Methylprednisolone (0.5 mg/kg) OR
- Cyclosporine OR
- IVIG OR
- Etanercept

With ideal management, fast recognition, in healthy patients...



Brigham and Women's Hospital
Founding Member, Mass General Brigham



**HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL**









CASE 3

64-year-old female with history of bullous pemphigoid, s/p rituximab with fevers daily and rash





Please take 30 seconds to write down a description of the rash:

- Confluent
- Violaceous
- Non-blanching
- ?Mucosal involvement
- Prominent Facial involvement
- Scattered papules



What additional information will help you assess this patient?

- HISTORY:
 - Medication history
 - Infection history
 - Immunologic status
- SYMPTOMS:
 - Skin pain vs skin itch
 - Mucosal involvement
- LABS:
 - CBC with DIFF, LFTs, BMP

Patient History

- 64-year-old female with history of bullous pemphigoid, s/p rituximab, prednisone 3 months ago
- Newly diagnosed gout → initiated on NSAIDs, colchicine.
- Following acute resolution, 6 weeks ago, uric acid level was elevated, and patient was initiated on allopurinol
- Beginning 2 week ago, developed fevers daily and rash



Labs

- Creatinine is 4 (from baseline of 1)
- Liver function tests are normal
- Absolute eosinophil count is 3000
- Atypical lymphocytes present on smear

*Based on the information provided
what is the most likely diagnosis?

- A. Stevens-Johnson's Syndrome (SJS)
- B. Acute generalized exanthematous pustulosis (AGEP)
- C. Morbilliform drug eruption
- D. Drug reaction with eosinophilia and systemic symptoms (DRESS)
- E. Infectious process

*Based on the information provided
what is the most likely diagnosis?

- A. Stevens-Johnson's Syndrome (SJS)
- B. Acute generalized exanthematous pustulosis (AGEP)
- C. Morbilliform drug eruption
- D. Drug reaction with eosinophilia and systemic symptoms (DRESS)
- E. Infectious process (THIS MUST BE RULED OUT TOO)

DRESS/DIHS

- Drug exposure 3 – 6 weeks prior to rash
- Rash: any morphology
- Exam findings: Fevers; Facial edema; LAD; Arthralgias/Arthritis
- Labs findings:
 - CBC abnormalities: Atypical lymphocytes; Eosinophilia
 - CMP abnormalities: Nephritis, elevated liver enzymes
 - Troponin elevation
 - Thyroiditis
 - HHV6/HHV7 reactivation



Non-specific rash



DIAGNOSTIC SCORING SYSTEM FOR DRESS/DIHS

Criteria	No	Yes	Unknown/ unclassifiable
Fever ($\geq 38.5^{\circ}\text{C}$)	-1	0	-1
Lymphadenopathy (≥ 2 sites; > 1 cm)	0	1	0
Circulating atypical lymphocytes	0	1	0
Peripheral hypereosinophilia 0.7–1.499 $\times 10^9/\text{L}$ - or - 10–19.9%* $\geq 1.5 \times 10^9/\text{L}$ - or - $\geq 20\%^*$	0	1 2	0
Skin involvement			
– Extent of cutaneous eruption $> 50\%$ BSA	0	1	0
– Cutaneous eruption suggestive of DRESS**	-1	1	0
– Biopsy suggests DRESS	1	0	0
Internal organs involved [†]	0		0
One		1	
Two or more		2	
Resolution in ≥ 15 days	-1	0	-1
Laboratory results negative for at least three of the following (and none positive): (1) ANA; (2) blood cultures; (3) HAV/HBV/HCV serology; and (4) <i>Chlamydia</i> and <i>Mycoplasma</i> serology	0	1	0
Final score: < 2 , no case; 2–3, possible case; 4–5, probable case; > 5 , definite case			
*If leukocytes $< 4.0 \times 10^9/\text{L}$			
**At least two of the following: edema, infiltration, purpura and scaling.			
[†] Liver, kidney, lung, muscle/heart, pancreas, or other organ and after exclusion of other explanations.			

Diagnosis


Table III. Diagnostic criteria for drug reaction with eosinophilia and systemic symptoms syndrome

Bocquet et al ⁴	RegiSCAR ⁷²	J-SCAR ^{73*}
Cutaneous drug eruption	Acute rash [†]	Maculopapular rash developing >3 weeks after starting offending drug
Hematologic abnormalities	Reaction suspected to be drug-related [†]	Prolonged clinical symptoms after discontinuation of the causative drug
Eosinophils $\geq 1.5 \times 10^9/L$	Hospitalization [†]	Fever $>38^\circ C$
Presence of atypical lymphocytes	Fever $>38^\circ C^\ddagger$	Liver abnormalities (ALT >100 U/L) or other organ involvement
Systemic involvement	Enlarged lymph nodes involving ≥ 2 sites [†]	Leukocyte abnormalities (≥ 1)
Adenopathy: lymph nodes ≥ 2 cm in diameter	Involvement of ≥ 1 internal organ [†]	Leukocytosis ($>11 \times 10^9/L$)
Hepatitis with liver transaminases ≥ 2 times normal	Blood count abnormalities [†]	Atypical lymphocytes ($>5\%$)
Interstitial nephritis	Lymphocytes above or below normal limits	Eosinophilia ($>1.5 \times 10^9/L$)
Interstitial pneumonitis	Eosinophils over laboratory limits	Lymphadenopathy
Carditis	Platelets under laboratory limits	HHV-6 reactivation



Table 2 Classification of Published DRESS Cases According to the RegiSCAR's Score¹¹

Drugs	Classification of DRESS cases n = 172				Nb of Cases n (%)
	No case n = 13 (8%)	Possible n = 35 (20%)	Probable n = 77 (45%)	Definite n = 47 (27%)	
Abacavir ¹²⁻¹⁶	4	1			5 (3)
Allopurinol ¹⁷⁻²⁹	1	6	8	4	19 (11)
Amoxicillin plus clavulanic acid ³⁰			1		1 (0.6)
Amitriptyline ^{31,32}			2		2 (1)
Atovarctatin ³³			1		1 (0.6)



Most Common Causes


- Allopurinol
- Anti-epileptics (carbamazepine, lamotrigine, phenobarbital)
- Sulfalazine

Spirolactone ¹²⁵			1	1 (0.6)	
Streptomycin ¹²⁶			1	1 (0.6)	
Strontium ranelate ¹²⁷			1	2 (1)	
Sulfalazine ^{62,93,128-135}	3		2	5	10 (6)
Sulfamethoxazole ^{14,136}			2		2 (1)
Tribenoside ¹³				1	1 (0.6)
Vancomycin ¹³⁷⁻¹⁴⁰	1		2	1	4 (2)
Zonisamide ¹⁸				1	1 (0.6)

DRESS = Drug Reaction with Eosinophilia and Systemic Symptom.

Cacoub et al. American Journal of Medicine 2011.

DRUG CHART



*What is the best treatment for this patient?

1. Supportive care
2. Low-dose prednisone (0.25 mg/kg) for 7 days
3. High-dose prednisone (1 mg/kg) for 2-4 weeks and slow taper
4. IV acyclovir for 7 days
5. Ibuprofen standing

*What is the best treatment for this patient?

1. Supportive care
2. Low-dose prednisone (0.25 mg/kg) for 7 days
3. High-dose prednisone (1 mg/kg) for 2-4 weeks and slow taper
4. IV acyclovir for 7 days
5. Ibuprofen standing



DRESS/DIHS MANAGEMENT

Bottom Line:

- If you have a high suspicion for DRESS/DIHS →
- AND the patient has signs of end stage organ dysfunction →
 - INTIATE prednisolone 1 mg/kg

Non severe

Daily clinical

*DILI \leq 1 (A)

without other organ involvement.

** Moderate to severe organ involvement. DILI \geq 2 (ALT \geq 5 ULN or AP \geq 2 ULN and TB \geq 2 ULN; AKI \geq 2 (Creatinine $>$ 2 – 2.9 times above baseline or urinary output $<$ 0.5/ml/kg/h $r >$ 12 hours, hemophagocytosis, pulmonary or cardiac involvement

Lack of control or contraindication for corticosteroids:

- Cyclosporine 4 - 5 mg / kg / day for 5 to 7 days and tapering
- IVIG 2 g / kg for 5 days
- Plasmapheresis




Fig 1. Algorithm for the diagnosis, management, and treatment of drug reaction with eosinophilia and systemic symptoms syndrome.

Case 4

A 65 year-old female with history of Stevens Johnson's Syndrome previously, presents with new rash and fevers.





Take 30 seconds to describe the exam




Full history

- A 65 year-old female with history of Stevens Johnson's Syndrome previously, presents with new rash and fevers.
- 14 days prior to developing rash, the patient started doxycycline for Lyme infection.
- She then developed atrial fibrillation with rapid ventricular response and was initiated on diltiazem 5 days prior to rash



DRUG CHART



What is the most likely diagnosis?

- A. Stevens-Johnson's Syndrome (SJS)
- B. Acute generalized exanthematous pustulosis (AGEP)
- C. Generalized impetigo
- D. Morbilliform drug eruption
- E. Drug reaction with eosinophilia and systemic symptoms (DRESS)

What is the most likely diagnosis?

- A. Stevens-Johnson's Syndrome (SJS)
- B. Acute generalized exanthematous pustulosis (AGEP)
- C. Generalized impetigo
- D. Morbilliform drug eruption
- E. Drug reaction with eosinophilia and systemic symptoms (DRESS)



Figure. Numerous Monomorphic Nonfollicular Pustules on a Background of Erythema on the Arm





Figure 1 Erythematous plaques and papules studded with sterile pustules, characteristic of typical acute generalized exanthematous pustulosis (AGEP).

JEADV 2015, 29, 209–214

AGEP (Acute Generalized Exanthematous Eruption)

- Acute rash that is associated with medication in 90% of cases (rarely viral infections in adults)
- Rash occurs quickly following exposure (**usually 2-5 days following exposure**)
- Generally rash self-resolves without intervention
- May require prednisone or other systemic medication

COMMON Drug causes

- Beta-lactam antibiotics (penicillins, aminopenicillins, cephalosporins)
- Macrolides (azithromycin)
- Calcium channel blockers (eg, diltiazem, nifedipine)
- Antimalarials
- Isoniazid
- Carbamazepine

Timeline

AGEP 48 hrs-2 weeks




MDE 7-10 days




SJS/TEN 1-3 weeks



DRESS 2-6 weeks



Drug Start



Brigham and Women's Hospital
Founding Member, Mass General Brigham



**HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL**

RASH	Skin Pain	Tell-tale sign	Urgent escalation of care needed?	Treatment
Morbilliform Drug	Rarely; generally itchy	Convincing drug, Convincing time course, no mucosal involvement	NO	Symptomatic and supportive
SJS	YES	Mucosal involvement, Skin desquamation or targets	YES	YES; Nursing care + immune suppression
DRESS	VARIABLE	Fevers, LAD, facial swelling, Lab abnormalities	YES	YES; 1 mg/kg prednisone
AGEP	YES + ITCH	Pustules or superficial skin peeling, fevers	NO	Symptomatic and supportive

Pearls

- All drug rashes can start looking the same
- Determine which camp you are in by timing, symptoms, and lab values
- Skin pain, gritty eye sensation, dysuria, dysphagia = BAD
- When calling a derm consult, describe what you see and where you see it (no need to use fancy terms) & relevant drug history (use fever tab!)
- MDE can spread more before it gets better, and resolves like a sunburn
- Treat all extensive drug rashes with fluids and lyte repletion, don't forget the skin!
- Need MULTIPLE tubes of topical steroids, nursing can ask this of pharmacy

Thank you!



DL